ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1686

Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts

Austin Ragland1, Michael Duryee1, nozima Aripova1, Spencer Jones1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: autoantigens, cytokines, Fibroblasts, Synovial, Gene Expression, Inflammation

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates intracellular calcium, thus potentially regulating function of calcium-dependent signal transduction leading to inflammation. As MAA strongly co-localizes with MGP in RA synovial tissues (Tieliwaerdi ACR 2020 abstract #0789), we have hypothesized that MGP is expressed by activated fibroblasts and that MAA-modification of this protein may increase the pool of intracellular calcium leading to production of pro-inflammatory cytokines.

Methods: As prior experiments have shown that stimulation with post-translationally modified proteins leads to fibroblast activation, HFLS-RA cells were stimulated with human fibrinogen (FIB) or human serum albumin (HSA) that were MAA-modified (FIB-MAA/HSA-MAA), citrullinated (FIB-CIT/HSA-CIT), or dually MAA- and CIT-modified (FIB-MAA-CIT/HSA-MAA-CIT). HFLS-RA cells were stained and analyzed for MGP expression using fluorescent immunohistochemistry (IHC) and quantified as the mean pixel density using ImageJ. HFLS-RA cells were then stimulated with MGP or MGP-MAA for 48 hours, mRNA isolated and RT-PCR performed for calcium signaling molecules: CABIN1, ORAI1 and NFATc1. Release of pro-inflammatory cytokines in HFLS-RA supernatants were measured by ELISA following stimulation with MGP vs. MGP-MAA.

Results: MGP expression was significantly increased in HFLS-RA cells following stimulation with all modified forms of FIB and HSA vs. native proteins (Figure 1). Additionally, MGP-MAA stimulated HFLS-RA cells significantly upregulated mRNA levels of all calcium-signaling proteins: CABIN1 (1.5-fold, p< 0.05), ORAI1 (1.7-fold, p< 0.001), and NFATc1 (1.7-fold, p< 0.001) (Figure 2) compared to cells stimulated with native MGP. Pro-inflammatory cytokine concentrations were increased in HFLS-RA supernatants following stimulation with MGP-MAA vs. native MGP (Figure 3).

Conclusion: IHC results demonstrate that HFLS-RA indeed express and upregulate MGP in response to MAA and/or CIT modified antigens. Moreover, MAA-modified MGP leads to the increased expression of CABIN1, which responds to changes in calcium, thereby increasing ORAI1 to open calcium channels and activate NFATC1 to signal the release of pro-inflammatory cytokines. Taken together, these findings suggest that MAA modifications act as a regulator of MGP function and potentiate calcium-dependent pathways leading to inflammation. Ongoing studies are focused on determining if this increase in cellular calcium also increases the citrullination of self-proteins via calcium-dependent pepitidylarginine deiminase (PAD) and the generation of autoantigens implicated in the pathogenesis of RA.

Supporting image 1

Figure 1. Fluorescent IHC for MGP expression in antigen stimulated HFLS-RA cells. HFLS-RA cells were stimulated with: A) modified HSA and B) modified FIB antigens. The data was quantified for MGP expression as Mean Pixel Density for C) modified HSA and D) modified FIB antigens. Comparisons were made to unmodified HSA or FIB, respectively: *p<0.001, #p<0.05, n=4.

Supporting image 2

Figure 2. PCR for mRNA levels of calcium signaling proteins from stimulated HFLS-RA cells. HFLS-RA cells were stimulated with either MGP or MGP-MAA and the following calcium binding proteins were measured: CABIN1, ORAI1 and NFATc1. The data is represented as mean (standard deviation) of relative quantity (Rq) of proteins. All the values are compared to unmodified MGP: *p<0.001, #p<0.05, n=4. Calcium signaling proteins: CABIN1 (calcineurin binding protein 1), ORAI1 (ORAI Calcium Release-Activated Calcium Modulator 1), NFATc1 (Nuclear Factor of Activated T cells 1).

Supporting image 3

Figure 3. ELISA data for pro-inflammatory cytokines released from stimulated HFLS-RA cells. HFLS-RA cells were stimulated with either MGP or MGP-MAA and the following cytokines were measured: A) IFN-γ, B) IL_12p70, C) IL_1β, D) TNF-α, E) IL-6, and F) IL-8. All the values are compared to native protein. Comparisons made to unmodified MGP: *p<0.001, #p<0.05, n=4.


Disclosures: A. Ragland, None; M. Duryee, None; n. Aripova, None; S. Jones, None; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc; G. Thiele, None.

To cite this abstract in AMA style:

Ragland A, Duryee M, Aripova n, Jones S, Mikuls T, Thiele G. Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/post-translational-modification-of-matrix-gla-protein-with-malondialdehyde-acetaldehyde-alters-cellular-responses-by-human-fibroblasts/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-translational-modification-of-matrix-gla-protein-with-malondialdehyde-acetaldehyde-alters-cellular-responses-by-human-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology